ONO PHARMACEUTICAL CO
🇯🇵Japan
ONO-4538 Phase II Rollover Study (ONO-4538-98)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 59
- Registration Number
- NCT04566380
- Locations
- 🇯🇵
Kanagawa Clinical Site1, Yokohama, Kanagawa, Japan
🇯🇵Tokyo Clinical Site3, Bunkyo-ku, Tokyo, Japan
🇯🇵Chiba Clinical Site2, Chiba, Japan
Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT04504760
- Locations
- 🇯🇵
Tokyo Clinical Site 01, Tokyo, Japan
Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 14
- Registration Number
- NCT04451083
- Locations
- 🇯🇵
Fukuoka Clinical Site 01, Fukuoka, Japan
ONO-7913 Phase I Study (ONO-7913)
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 7
- Registration Number
- NCT04403308
- Locations
- 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan
Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 78
- Registration Number
- NCT04079062
- Locations
- 🇯🇵
Fukuoka Clinical Site, Hakata, Fukuoka, Japan
A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT03919890
- Locations
- 🇬🇧
Hammersmith Medicines Research (HMR), London, United Kingdom
Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT03849872
- Locations
- 🇳🇱
PRA-EDS, Groningen, NZ, Netherlands
Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT03730337
- Locations
- 🇯🇵
Tokyo Clinical Site, Tokyo, Japan
A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 76
- Registration Number
- NCT03571594
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 1
- Registration Number
- NCT03182257
- Locations
- 🇺🇸
Greenville Hospital System University Medical Center, Greenville, South Carolina, United States
🇺🇸Mount Sinai, New York, New York, United States
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath